Trial Profile
A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 06 Apr 2022 The trial has been completed in Norway, according to European Clinical Trials Database record.
- 13 Oct 2021 Status changed from completed to discontinued.
- 02 Apr 2019 Status changed from recruiting to completed.